[ad_1] Steven McIntoshEntertainment reporterGetty ImagesThe closing credits of 2021's No Time To Die, the most recent film in the 007 series, ended with a familiar message: "James Bond will return."But for the last few years,…
Stocks to buy for short term: Lupin, Welspun…
[ad_1] Stocks to buy for short term: The domestic benchmark Nifty 50 ended with a healthy gain of about 0.70 per cent on Tuesday, reclaiming the 25,200 level on optimism over India–US trade talks and…
Lupin CFO Ramesh Swaminathan on GST, US tariffs,…
[ad_1] In an exclusive conversation with ETCFO, Ramesh Swaminathan, Group CFO of Lupin, outlined the company’s capital allocation strategy, growth priorities, and policy expectations from the Indian government. Swaminathan said Lupin is actively exploring acquisitions…
Top Gainers and Losers on August 07: ITI,…
[ad_1] Indian stocks staged a sharp recovery in Thursday's trade, recouping all the losses incurred during the first half of the session and turning positive towards the close. The markets opened on a weak note…
From Laurus Labs, Lupin to Biocon— Pharma stocks…
[ad_1] Pharma stocks exhibited remarkable resilience in the morning trade on Wednesday, July 9, despite US President Donald Trump's threat of a very high tariff of up to 200 per cent.Several pharma stocks, including Laurus…
Aurobindo Pharma, Lupin to Natco Pharma: Why is…
[ad_1] Indian pharmaceutical stocks tumbled sharply on Tuesday, June 17, after US President Donald Trump warned that tariffs on pharmaceutical imports would be imposed “very soon.” The Nifty Pharma index slumped over 2 percent to…
Q4 results today: Tata Power, Eicher Motors, Lupin,…
[ad_1] Q4 results on May 14: Eicher Motors, Tata Power, Lupin, Apollo Tyres, Muthoot Finance, Jubilant Foodworks, Shree Cements, Sagility, and Berger Paints India are among at least 116 companies scheduled to release their Q4FY25…
Stocks to watch: Maruti Suzuki, Bharti Airtel, HDFC…
[ad_1] Here’s a quick look at stocks likely to be in focus in today's trade.Maruti SuzukiCountry's largest car manufacturer plans to raise prices on seven models starting April 8, citing higher input costs, operational expenses,…
Kotak Equities is optimistic on Indian pharma despite…
[ad_1] In light of uncertainties surrounding US tariffs on pharmaceuticals, Kotak Institutional Equities noted in a recent report that the most likely scenario (for both companies and investors) is that high tariffs (above 10%) are…